Company news
Xspray Pharma AB news in 2026
Xspray Pharma AB's news releases, calls and decks from 2026, newest first.
Xspray’s rights issue oversubscribed – over-allotment issue fully utilized
April 23, 2026
Xspray publishes disclosure document regarding rights issue
March 31, 2026
Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased
March 26, 2026
Xspray Pharma publishes its Annual Report 2025
March 26, 2026
Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue
March 24, 2026
Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc® – PDUFA date August 25, 2026
March 11, 2026
Xspray Pharma re-submits its FDA application for Dasynoc
February 26, 2026
Xspray Pharma appoints Blake Leitch as CEO – Per Andersson continues as Chief Scientific Officer (CSO)
February 26, 2026